Janux Therapeutics To Host Virtual Event On Monday, December 2, 2024, At 4:30 PM ET Discussing Updated Clinical Data In Phase 1a Dose Escalation For JANX007 In MCRPC And Doses Selected For Phase 1b Expansion Studies
Janux Therapeutics To Host Virtual Event On Monday, December 2, 2024, At 4:30 PM ET Discussing Updated Clinical Data In Phase 1a Dose Escalation For JANX007 In MCRPC And Doses Selected For Phase 1b Expansion Studies
The virtual event will take place on Monday, December 2, 2024, at 4:30 PM ET
虛擬活動將在2024年12月2日星期一東部時間下午4:30舉行
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced it will host a virtual event on Monday, December 2, 2024, at 4:30 PM ET.
Janux Therapeutics, Inc. (納斯達克:JANX) (Janux)是一家臨床階段的生物製藥公司，通過應用其專有科技於腫瘤激活T細胞連接器（TRACTr）和腫瘤激活免疫調節器（TRACIr）平台，開發了一系列新型免疫療法。今天宣佈，它將在2024年12月2日星期一東部時間下午4:30舉辦一次虛擬活動。
David Campbell, Ph.D., President & Chief Executive Officer, will provide an update on JANX007 Phase 1a dose escalation data and doses selected for Phase 1b expansion studies in adult subjects with metastatic castration-resistant prostate cancer (mCRPC).
大衛·坎貝爾博士，總裁兼首席執行官，將提供關於JANX007第一階段劑量遞增數據和爲患有轉移性去勢抵抗前列腺癌（mCRPC）成年受試者選擇的10億擴展研究劑量的最新信息。
譯文內容由第三人軟體翻譯。
